Table 3

Antifungal therapy (N = 412 patients)
Description VORI CASPO FLUC ITRA AMB POSA MICA ANID
Used drug at least once (%) 292 (70.87) 161 (39.08) 117 (28.40) 34 (8.25) 53 (12.86) 3 (0.73) 13 (3.16) 9 (2.18)
Used as initial monotherapy (%) (N = 354) 166 (46.89) 63 (17.80) 98 (27.68) 12 (3.39) 12 (3.39) 0 (0.00) 2 (0.56) 1 (0.28)
Used as initial combination therapy (%) (N = 58) 53 (91.38) 38 (65.51) 4 (6.90) 10 (12.50) 9 (11.25) 3 (5.08) 5 (8.62) 5 (8.62)
Length of initial therapy, days (SD) 12.1 (12.3) 9.1 (8.4) 6.0 (4.7) 8.4 (11.3) 7.3 (8.3) 14.3 (18.0) 7.7 (6.6) 10.6 (10.3)
 Length of initial therapy (Survivors) 12.8 (12.6) 10.9 (7.7) 6.7 (5.0) 9.4 (12.6) 7.1 (6.9) 14.3 (18.0) 8.7 (7.8) 11.3 (10.8)
 Length of initial therapy (Non-survivors) 11.2 (12.0) 7.2 (8.8) 6.4 (4.5) 6.1 (7.2) 7.4 (9.1) - 6.5 (5.2) 5.0 (−)
Mortality (% who received drug at least once) 125 (42.81) 79 (49.07) 66 (48.89) 10 (29.41) 33 (62.26) 0 (0.00) 6 (46.15) 1 (11.11)
Hospital admission to discharge, days (SD) 27.8 (26.3) 31.1 (31.1) 33.9 (24.2) 28.9 (19.5) 30.7 (25.2) 31.0 (21.2) 25.3 (17.0) 32.8 (20.7)
Drug initiation to discharge, days (SD) 19.2 (21.7) 21.0 (26.1) 25.1 (22.4) 21.7 (16.3) 23.2 (23.2) 24.0 (18.0) 20.5 (18.4) 26.3 (15.3)

VORI, voriconazole; CASPO, caspofungin; FLUC, fluconazole; ITRA, itraconazole; POSA, posaconazole; MICA, micafungin; ANID, anidulafungin.

SD=standard deviation.

Baddley et al.

Baddley et al. BMC Infectious Diseases 2013 13:29   doi:10.1186/1471-2334-13-29

Open Data